ADME Sequencing

Ambry Genetics has partnered with RainDance Technologies to develop a comprehensive genomic screening panel to sequence the coding regions for genes implicated in drug absorption, distribution, metabolism, and excretion (ADME) research for use on next-generation sequencing platforms.

The RainDance ADMESeq Extended Screening Panel enables researchers to simultaneously interrogate 242 known pharmacokinetic and pharmacology genes. The panel leverages RainDance’s proprietary primer design pipeline to target greater than 98 percent of the exons to provide highly accurate, consistent, and reproducible results required in ADME research and for most FDA drug applications. Our team of experts is here to help you reach your project goals.

Capabilities:

Simultaneously sequence 242 key ADME genes, including:
44 membrane transporters
86 genes with FDA-approved drugs with pharmacogenomic information in their labels
42 of the VIP genes from the Pharmacogenomics Knowlegbase
Whole genome + targeted array: Increased probe coverage in exons of over 400 cancer associated genes, including over 70 genes mostly associated with germline
Variations 20 kb overall median probe spacing
~5.1 probes per exon in over 400 targeted genes

Features:

Sequence Coverage: 20x coverage for >98% of the targeted regions
Concordance with HapMap SNPs: >97% concordance to HapMap genotypes (n=16)
Greater Uniformity: >90% base coverage within 0.2x of the mean

Advantages:

Certified Service Provider for Illumina, Ion Torrent, Agilent, RainDance and Roche NimbleGen
Collaborated on thousands of projects
Consistently high quality data and robust analysis
Cost-effective and fast turnaround times
Initial project planning teleconferences with our scientific team
MD and PhD scientists available for personalized scientific consultation and project management
CAP accredited and CLIA certified reference laboratory

Platforms